Clinical outcomes of metabolic surgery: Efficacy of glycemic control, weight loss, and remission of diabetes

Philip R. Schauer, Geltrude Mingrone, Sayeed Ikramuddin, Bruce Wolfe

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Since the 2007 Diabetes Surgery Summit in Rome, Italy, and the subsequent publishing of the world's first guidelines for the surgical treatment of type 2 diabetes (T2D), much new evidence regarding the efficacy and safety of metabolic surgery has emerged. Additional observational cohort studies support the superior effects of surgery over medical treatment with respect to glycemic control, weight loss, and even reduction in mortality and microvascular complications associated with T2D. Furthermore, new safety data suggest that the perioperative morbidity and mortality of metabolic surgery (5% and 0.3%, respectively) are now similar to that of common low-risk procedures, such as cholecystectomy and hysterectomy. The largest advance, however, has been the completion of 11 randomized controlled trials from around the globe that compare surgery with medical treatment of T2D. These studies with follow-up duration of 1-5 years involve nearly 800 patients without surgical mortality and with major complication rates of less than 5% and a reoperation rate of 8%. All but 1 of the 11 randomized controlled trials have shown the superiority of surgery over medical management at achieving remission or glycemic improvement. Surgery was also superior to medical treatment with respect to improving cardiovascular risk factors, such as weight loss and dyslipidemia, while reducing medication burden. This new efficacy and safety evidence should help guide physicians across the globe to the appropriate use of surgery as an effective treatment for patients suffering from T2D and obesity.

Original languageEnglish (US)
Pages (from-to)902-911
Number of pages10
JournalDiabetes Care
Volume39
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Bariatric Surgery
Weight Loss
Type 2 Diabetes Mellitus
Safety
Mortality
Randomized Controlled Trials
Therapeutics
Cholecystectomy
Dyslipidemias
Hysterectomy
Reoperation
Italy
Observational Studies
Cohort Studies
Obesity
Guidelines
Morbidity
Physicians

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Clinical outcomes of metabolic surgery : Efficacy of glycemic control, weight loss, and remission of diabetes. / Schauer, Philip R.; Mingrone, Geltrude; Ikramuddin, Sayeed; Wolfe, Bruce.

In: Diabetes Care, Vol. 39, No. 6, 01.06.2016, p. 902-911.

Research output: Contribution to journalArticle

Schauer, Philip R. ; Mingrone, Geltrude ; Ikramuddin, Sayeed ; Wolfe, Bruce. / Clinical outcomes of metabolic surgery : Efficacy of glycemic control, weight loss, and remission of diabetes. In: Diabetes Care. 2016 ; Vol. 39, No. 6. pp. 902-911.
@article{488480f51f9e46068395c38954c1d3cb,
title = "Clinical outcomes of metabolic surgery: Efficacy of glycemic control, weight loss, and remission of diabetes",
abstract = "Since the 2007 Diabetes Surgery Summit in Rome, Italy, and the subsequent publishing of the world's first guidelines for the surgical treatment of type 2 diabetes (T2D), much new evidence regarding the efficacy and safety of metabolic surgery has emerged. Additional observational cohort studies support the superior effects of surgery over medical treatment with respect to glycemic control, weight loss, and even reduction in mortality and microvascular complications associated with T2D. Furthermore, new safety data suggest that the perioperative morbidity and mortality of metabolic surgery (5{\%} and 0.3{\%}, respectively) are now similar to that of common low-risk procedures, such as cholecystectomy and hysterectomy. The largest advance, however, has been the completion of 11 randomized controlled trials from around the globe that compare surgery with medical treatment of T2D. These studies with follow-up duration of 1-5 years involve nearly 800 patients without surgical mortality and with major complication rates of less than 5{\%} and a reoperation rate of 8{\%}. All but 1 of the 11 randomized controlled trials have shown the superiority of surgery over medical management at achieving remission or glycemic improvement. Surgery was also superior to medical treatment with respect to improving cardiovascular risk factors, such as weight loss and dyslipidemia, while reducing medication burden. This new efficacy and safety evidence should help guide physicians across the globe to the appropriate use of surgery as an effective treatment for patients suffering from T2D and obesity.",
author = "Schauer, {Philip R.} and Geltrude Mingrone and Sayeed Ikramuddin and Bruce Wolfe",
year = "2016",
month = "6",
day = "1",
doi = "10.2337/dc16-0382",
language = "English (US)",
volume = "39",
pages = "902--911",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical outcomes of metabolic surgery

T2 - Efficacy of glycemic control, weight loss, and remission of diabetes

AU - Schauer, Philip R.

AU - Mingrone, Geltrude

AU - Ikramuddin, Sayeed

AU - Wolfe, Bruce

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Since the 2007 Diabetes Surgery Summit in Rome, Italy, and the subsequent publishing of the world's first guidelines for the surgical treatment of type 2 diabetes (T2D), much new evidence regarding the efficacy and safety of metabolic surgery has emerged. Additional observational cohort studies support the superior effects of surgery over medical treatment with respect to glycemic control, weight loss, and even reduction in mortality and microvascular complications associated with T2D. Furthermore, new safety data suggest that the perioperative morbidity and mortality of metabolic surgery (5% and 0.3%, respectively) are now similar to that of common low-risk procedures, such as cholecystectomy and hysterectomy. The largest advance, however, has been the completion of 11 randomized controlled trials from around the globe that compare surgery with medical treatment of T2D. These studies with follow-up duration of 1-5 years involve nearly 800 patients without surgical mortality and with major complication rates of less than 5% and a reoperation rate of 8%. All but 1 of the 11 randomized controlled trials have shown the superiority of surgery over medical management at achieving remission or glycemic improvement. Surgery was also superior to medical treatment with respect to improving cardiovascular risk factors, such as weight loss and dyslipidemia, while reducing medication burden. This new efficacy and safety evidence should help guide physicians across the globe to the appropriate use of surgery as an effective treatment for patients suffering from T2D and obesity.

AB - Since the 2007 Diabetes Surgery Summit in Rome, Italy, and the subsequent publishing of the world's first guidelines for the surgical treatment of type 2 diabetes (T2D), much new evidence regarding the efficacy and safety of metabolic surgery has emerged. Additional observational cohort studies support the superior effects of surgery over medical treatment with respect to glycemic control, weight loss, and even reduction in mortality and microvascular complications associated with T2D. Furthermore, new safety data suggest that the perioperative morbidity and mortality of metabolic surgery (5% and 0.3%, respectively) are now similar to that of common low-risk procedures, such as cholecystectomy and hysterectomy. The largest advance, however, has been the completion of 11 randomized controlled trials from around the globe that compare surgery with medical treatment of T2D. These studies with follow-up duration of 1-5 years involve nearly 800 patients without surgical mortality and with major complication rates of less than 5% and a reoperation rate of 8%. All but 1 of the 11 randomized controlled trials have shown the superiority of surgery over medical management at achieving remission or glycemic improvement. Surgery was also superior to medical treatment with respect to improving cardiovascular risk factors, such as weight loss and dyslipidemia, while reducing medication burden. This new efficacy and safety evidence should help guide physicians across the globe to the appropriate use of surgery as an effective treatment for patients suffering from T2D and obesity.

UR - http://www.scopus.com/inward/record.url?scp=84971201943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971201943&partnerID=8YFLogxK

U2 - 10.2337/dc16-0382

DO - 10.2337/dc16-0382

M3 - Article

C2 - 27222548

AN - SCOPUS:84971201943

VL - 39

SP - 902

EP - 911

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -